Cancer Scientist: This Common Daily Diet May Be Feeding Cancer! - Thomas Seyfried

Thomas Seyfried argues that the prevailing field of cancer research misunderstands the origin of cancer, asserting it stems from damage to mitochondria. He emphasizes that chronic diseases and cancer are fundamentally linked to this mitochondrial dysfunction, a perspective he believes is tragically overlooked by many in the scientific community.

Seyfried highlights how modern lifestyles negatively impact mitochondrial health. He points to the prevalence of highly processed carbohydrates, lack of physical activity, emotional stress, and poor sleep habits as key contributors to chronic damage of this vital organelle. This is contrasted with wild animals like wolves who thrive on natural diets and exercise.

Seyfried credits Otto Warberg’s research from the 1920s-40s for identifying cancer as a metabolic disease rooted in mitochondrial dysfunction. Warburg demonstrated that cancer cells exhibit altered metabolism, relying on glycolysis rather than oxidative phosphorylation, which is characteristic of healthy mitochondria. Seyfried believes this foundational discovery has been largely ignored by mainstream cancer treatment approaches.

Seyfried explains that mitochondria are crucial for determining lifespan, with different species exhibiting varying lifespans directly correlated to the health and efficiency of these organelles. He notes that wrinkles and signs of aging are a consequence of wear and tear on mitochondria as they work to produce energy, emphasizing their vital role in overall longevity.

Albert St. Gorgi, a Nobel laureate for his work on vitamin C, introduced the ankcogenic paradox, highlighting the disconnect between known cancer-inducing factors (viruses, inflammation, etc.) and the underlying mechanism causing uncontrolled cell growth. He observed that while we identify triggers for cancer, we lack understanding of how they lead to disregulated cell division, which is the core characteristic of cancer – cells dividing uncontrollably due to a compromised organelle.

Seyfried explains that mitochondria, the organelles regulating cell division, originated from ancient bacteria billions of years ago. Initially, these bacteria functioned independently, prioritizing their own growth without coordinating with other cells. Although now integrated into a larger organism and functioning collaboratively, damaged mitochondria can revert to this 'selfish' mode, contributing to uncontrolled cell growth characteristic of cancer.

Otto Warberg proposed that cancer is fundamentally an energy problem within cells, noting the unusual phenomenon of cancer cells producing large amounts of lactic acid even in the presence of oxygen. He theorized this was due to irreversible damage to the mitochondria and a failure to properly utilize oxygen for energy production, a hypothesis initially met with skepticism but later supported by research.

Contrary to initial assumptions that cancer cells were not utilizing oxygen, Seyfried’s team demonstrated that while cancer cells do consume oxygen, they aren't using it for ATP production. Instead, the oxygen is being used to generate reactive oxygen species (ROS), which damage DNA and contribute to further mutations—effectively highlighting a downstream effect of mitochondrial dysfunction.

Thomas Seyfried observes a strong correlation between high cancer rates and countries like Australia, New Zealand, and the United States. He attributes this to a combination of factors including readily available highly processed carbohydrates, inactivity, emotional stress, poor sleep habits, exposure to carcinogens, and damage to cellular organelles. This contrasts with populations adhering to traditional lifestyles.

Seyfried emphasizes the crucial role of mitochondrial health in cancer prevention. He explains that our ancestors, and modern populations living traditionally with minimal dietary or lifestyle interference, exhibit lower cancer rates due to healthier mitochondria. This highlights the importance of maintaining mitochondrial function to reduce overall disease risk.

Seyfried clarifies that while genetic mutations like BRCA1 and Li-Fraumeni syndrome are associated with increased cancer risk, they are not primary drivers. Instead, he explains that these mutations act as secondary risk factors, disturbing the efficiency of oxidative phosphorylation within mitochondria, a process vital for cellular energy production.

Seyfried explains that viral infections like hepatoma and papilloma can directly damage mitochondria. These viruses either replicate within the organelle or produce substances that disrupt its function, leading to compensatory fermentation, disregulated cell growth, abnormal calcium signaling, and ultimately contributing to cancer development.

Seyfried emphasizes that cancer cells, due to damage to their organelles, are unable to efficiently burn ketones for energy. They rely primarily on glucose metabolism and accumulate lipid droplets as a protective mechanism against fatty acid oxidation. This inability to utilize ketones is a critical factor in the effectiveness of metabolic therapies targeting cancer.

The development of the GKI was directly inspired by Trudy Dupant, a lawyer with a brain stem glioma who utilized metabolic therapy to extend her life for over 10 years. Her fluctuating blood sugar levels despite adhering to a ketogenic diet prompted Seyfried and his team to develop the GKI as a more stable metric than measuring glucose and ketones independently. This case underscored the need for a combined measurement to accurately assess metabolic status in individuals with cancer.

Thomas Seyfried explains that the GKI, a ratio of glucose to ketones, is not merely an indicator of metabolic state but also reflects the health and efficiency of mitochondria. A lower GKI indicates healthier mitochondria, mirroring the metabolic profile of Paleolithic humans who experienced periods of ketosis due to limited food availability and high activity levels. This state is associated with a reduced risk of chronic diseases because mitochondrial function is optimal.

Seyfried draws parallels between the GKI and the dietary habits of Paleolithic humans, who frequently existed in a state of ketosis due to limited food availability and high physical activity. He posits that this metabolic state, characterized by a low GKI, contributed to the absence of chronic diseases common in modern populations. The current prevalence of pastries and sweets is a deviation from this ancestral pattern.

Research suggests that entering a state of ketosis can act as a supportive therapy, enhancing the cancer-killing effects of chemotherapy while simultaneously protecting healthy cells. This occurs because during ketosis, healthy cells enter a 'bunker mode,' slowing their division and conserving energy, whereas cancer cells continue to rapidly divide, making them more vulnerable to chemotherapy's toxic effects.

Employing a ketogenic diet and fasting creates metabolic pressure that shrinks tumors, rendering them less aggressive. This also improves the patient's overall health by preventing common chemotherapy side effects like hair loss, bleeding gums, and microbiome disruption. Subsequently, low-dose chemotherapy and immunotherapy can be administered more effectively against any remaining cancer cells.

Cancer cells produce lactic acid and succinic acid as waste products during fermentation. These byproducts act as a shield, preventing chemotherapy and radiation from effectively targeting the tumor. To enhance treatment efficacy, it's crucial to target both glucose and glutamine fuels simultaneously, removing this protective barrier.

The vast majority of mainstream oncologists do not recommend ketogenic diets to newly diagnosed patients. This reluctance stems primarily from the fear of exacerbating cachexia, a severe wasting syndrome common in cancer patients and associated with mortality, as keto diets can lead to weight loss.

Thomas Seyfried emphasizes that government or officials should not dictate what people eat. He advocates for patient empowerment, stating that individuals need to be knowledgeable and make informed choices about their diet based on personal understanding rather than external mandates. This approach encourages self-responsibility and a deeper engagement with health decisions.

Seyfried discusses the importance of ketones for maintaining cellular bioenergetic efficiency. He questions whether GLP-1 medications, which lower blood sugar, also raise ketone levels, as it's the ketones that contribute to organel health and potentially reduce conditions like dementia, diabetes, and obesity. This highlights a crucial aspect of metabolic health beyond just glucose management.

Beyond diet, Seyfried outlines several key strategies for cancer prevention including education, addressing food deserts to provide access to healthy options, regular exercise, and stress reduction through methods like music therapy or meditation. He presents a humorous scenario illustrating the consequences of neglecting these preventative measures.

Seyfried discusses the development of apps utilizing AI and continuous glucose/ketone monitors that allow individuals to photograph food items and instantly determine their impact on metabolic zones. This technology aims to empower patients by providing immediate feedback and facilitating informed dietary choices, aligning with his philosophy of patient-driven health management.

Thomas Seyfried discusses the prevalence of heavy metals and chemicals in public water supplies, often due to runoff and inadequate filtration. He highlights that carcinogens like arsenic and cacadium are classified as Group 1 carcinogens by IARC. Crucially, he notes that nearly every chemical they've studied linked to oncology or disregulated cell growth chronically damages oxidative phosphorylation, emphasizing the need to protect this organelle.

Seyfried explains that while localized tumors have a higher probability of successful therapy, the spread of cancer (metastasis) is what predominantly causes death. When a tumor spreads from, for example, the breast to the liver and lungs, treatment becomes significantly more challenging due to systemic involvement and the difficulty in targeting these distant sites.

Seyfried introduces a unique concept: stem cell tumors, which he states cannot metastasize. He explains that when the immune system recognizes these tumors as 'unhealed wounds,' it fuses with the stem cells to create hybrid macrofagage tumor cells. These hybrid cells are programmed to move throughout the body and are responsible for metastasis.

Seyfried details how metastatic cancer cells are 'glutamine driven,' meaning they rely heavily on glutamine and glucose for survival. He advocates for metabolic therapy, specifically a 'press pulse' strategy where glucose is suppressed followed by a pulse to kill glutamine, which effectively targets these metastatic cells while promoting organ health.